Personalis PSNL Stock
Personalis Price Chart
Personalis PSNL Financial and Trading Overview
| Personalis stock price | 3.84 USD |
| Previous Close | 2.15 USD |
| Open | 2.12 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 2.12 - 2.18 USD |
| 52 Week Range | 1.73 - 5.58 USD |
| Volume | 100.24K USD |
| Avg. Volume | 304.61K USD |
| Market Cap | 100.59M USD |
| Beta (5Y Monthly) | 1.422313 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.37 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.17 USD |
PSNL Valuation Measures
| Enterprise Value | 1.13M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.143617 |
| PEG Ratio (5 yr expected) | 0.07 |
| Price/Sales (ttm) | 1.4645482 |
| Price/Book (mrq) | 0.5193237 |
| Enterprise Value/Revenue | 0.016 |
| Enterprise Value/EBITDA | -0.011 |
Trading Information
Personalis Stock Price History
| Beta (5Y Monthly) | 1.422313 |
| 52-Week Change | -34.25% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.58 USD |
| 52 Week Low | 1.73 USD |
| 50-Day Moving Average | 2.3 USD |
| 200-Day Moving Average | 2.64 USD |
PSNL Share Statistics
| Avg. Volume (3 month) | 304.61K USD |
| Avg. Daily Volume (10-Days) | 283.44K USD |
| Shares Outstanding | 46.78M |
| Float | 37.68M |
| Short Ratio | 4.28 |
| % Held by Insiders | 2.40% |
| % Held by Institutions | 77.59% |
| Shares Short | 1.39M |
| Short % of Float | 4.22% |
| Short % of Shares Outstanding | 2.97% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -165.64% |
| Operating Margin (ttm) | -161.85% |
| Gross Margin | 20.09% |
| EBITDA Margin | -148.11% |
Management Effectiveness
| Return on Assets (ttm) | -21.28% |
| Return on Equity (ttm) | -47.36% |
Income Statement
| Revenue (ttm) | 68.68M USD |
| Revenue Per Share (ttm) | 1.49 USD |
| Quarterly Revenue Growth (yoy) | 23.89% |
| Gross Profit (ttm) | 13.35M USD |
| EBITDA | -101726000 USD |
| Net Income Avi to Common (ttm) | -113765000 USD |
| Diluted EPS (ttm) | -2.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 148.94M USD |
| Total Cash Per Share (mrq) | 3.18 USD |
| Total Debt (mrq) | 49.48M USD |
| Total Debt/Equity (mrq) | 25.55 USD |
| Current Ratio (mrq) | 5.353 |
| Book Value Per Share (mrq) | 4.14 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -74621000 USD |
| Levered Free Cash Flow (ttm) | -101744248 USD |
Profile of Personalis
| Country | United States |
| State | CA |
| City | Fremont |
| Address | 6600 Dumbarton Circle |
| ZIP | 94555 |
| Phone | 650 752 1300 |
| Website | https://www.personalis.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 395 |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.
Q&A For Personalis Stock
What is a current PSNL stock price?
Personalis PSNL stock price today per share is 3.84 USD.
How to purchase Personalis stock?
You can buy PSNL shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Personalis?
The stock symbol or ticker of Personalis is PSNL.
Which industry does the Personalis company belong to?
The Personalis industry is Diagnostics & Research.
How many shares does Personalis have in circulation?
The max supply of Personalis shares is 88.31M.
What is Personalis Price to Earnings Ratio (PE Ratio)?
Personalis PE Ratio is now.
What was Personalis earnings per share over the trailing 12 months (TTM)?
Personalis EPS is -1.37 USD over the trailing 12 months.
Which sector does the Personalis company belong to?
The Personalis sector is Healthcare.
Personalis PSNL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4148.65 USD — |
+0.54
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4131.38 USD — |
-1.41
|
— — | 4109.33 USD — | 4165.2 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}